Abbott Laboratories (NYSE:ABT) Falls Short of Q4 CY2025 Revenue Projections, Shares Decline

Abbott Laboratories Q4 2025 Earnings Overview

Abbott Laboratories (NYSE: ABT), a leading provider of healthcare products and medical devices, reported fourth-quarter 2025 results that did not meet market revenue forecasts. The company posted $11.46 billion in sales for the quarter, reflecting a 4.4% increase compared to the same period last year. Adjusted earnings per share came in at $1.50, matching Wall Street’s expectations.

Highlights from Q4 2025

• Total Revenue: $11.46 billion, falling short of the $11.8 billion analyst consensus (4.4% year-over-year growth, 2.9% below estimates)
• Adjusted EPS: $1.50, in line with the $1.49 analyst forecast
• 2026 Adjusted EPS Guidance: Midpoint set at $5.68, consistent with analyst projections
• Operating Margin: 19.6%, an improvement from 17.4% in the prior year’s quarter
• Organic Revenue: Up 3% year-over-year, but below expectations
• Market Cap: $209.9 billion

“In 2025, we improved our margins, delivered double-digit EPS growth, launched a robust pipeline of new products, and made strategic moves to position Abbott for long-term success,” commented Robert B. Ford, Chairman and CEO of Abbott Laboratories.

About Abbott Laboratories

Founded in 1888 by Dr. Wallace Abbott, the company has a long history of innovation in healthcare. Today, Abbott Laboratories develops and markets a broad portfolio of products, including medical devices, diagnostic tools, nutritional supplements, and branded generic medicines.

Revenue Performance

Assessing a company’s growth over time provides valuable insight into its quality. While short-term results can fluctuate, sustained expansion is a hallmark of strong businesses. Over the past five years, Abbott Laboratories achieved a compound annual revenue growth rate of 5.1%, which is modest compared to other healthcare peers, though there are still positive aspects to consider.

Abbott Laboratories Quarterly Revenue

Although long-term growth is crucial, the healthcare sector can experience shifts due to innovation or changing demand. Abbott’s two-year annualized revenue growth of 5.1% mirrors its five-year average, indicating steady but subdued demand.

Abbott Laboratories Year-On-Year Revenue Growth

To better understand underlying trends, it’s helpful to examine organic revenue, which excludes the impact of acquisitions and currency changes. Over the last two years, Abbott’s organic revenue grew by an average of 6.4% annually. This suggests that the company’s core business, rather than external factors, has been the main driver of its performance.

Abbott Laboratories Organic Revenue Growth

For the latest quarter, revenue increased 4.4% year-over-year to $11.46 billion, missing analyst expectations. Looking forward, analysts anticipate an 8.8% rise in revenue over the next year, a notable acceleration for a company of Abbott’s size, likely fueled by new product launches and services.

Profitability and Margins

Abbott Laboratories has maintained strong cost control over the past five years, achieving an average operating margin of 17.9%, which is solid for the healthcare sector.

Looking at profitability trends, the company’s operating margin declined by 1.4 percentage points over five years but improved by 2 points in the last two years. This recent uptick is encouraging and suggests operational improvements.

Abbott Laboratories Trailing 12-Month Operating Margin (GAAP)

In the fourth quarter, Abbott’s operating margin reached 19.6%, up 2.2 percentage points from the previous year, reflecting greater efficiency.

Earnings Per Share Analysis

While revenue growth shows how a company expands, long-term changes in earnings per share (EPS) reveal how profitable that growth is. Sometimes, companies can boost sales by spending heavily on marketing, which doesn’t always translate to higher profits.

Abbott’s EPS has grown at a 7.1% compound annual rate over the past five years, outpacing its revenue growth. However, since operating margins did not improve, this EPS growth was not driven by operational efficiency alone.

Abbott Laboratories Trailing 12-Month EPS (Non-GAAP)

A closer look reveals that Abbott has reduced its share count by 2.3% over five years through stock buybacks. This financial strategy has helped boost EPS, even though it wasn’t accompanied by significant margin expansion.

Abbott Laboratories Diluted Shares Outstanding

For Q4, adjusted EPS was $1.50, up from $1.34 a year earlier and in line with analyst expectations. Wall Street projects full-year EPS to reach $5.15 over the next 12 months, representing a 9.9% increase.

Summary of Q4 Results

Overall, the latest quarter was underwhelming for Abbott Laboratories. Both total and organic revenue missed expectations, and the company’s shares dropped 5.5% to $114.10 following the report.

While one quarter doesn’t define a company’s long-term prospects, it’s important to consider valuation, business fundamentals, and recent performance when evaluating whether to invest in Abbott Laboratories.